Genetic Polymorphisms of MDM2 and TP53 Genes Are Associated with Risk of Nasopharyngeal Carcinoma in a Chinese Population

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Apr 20

PMID 20398418

Citations 15

Authors

Mang Xiao

Lei Zhang

Xinhua Zhu

Jun Huang

Huifen Jiang

Sunhong Hu

Yuehui Liu

Affiliations

Soon will be listed here.

Abstract

Background: The tumor suppressor TP53 and its negative regulator MDM2 play crucial roles in carcinogenesis. Previous case-control studies also revealed TP53 72Arg>Pro and MDM2 309T>G polymorphisms contribute to the risk of common cancers. However, the relationship between these two functional polymorphisms and nasopharyngeal carcinoma (NPC) susceptibility has not been explored.

Methods: In this study, we performed a case-control study between 522 NPC patients and 722 healthy controls in a Chinese population by using PCR-RFLP.

Results: We found an increased NPC risk associated with the MDM2 GG (odds ratio [OR] = 2.83, 95% confidence interval [CI] = 2.08-3.96) and TG (OR = 1.49, 95% CI = 1.16-2.06) genotypes. An increased risk was also associated with the TP53 Pro/Pro genotype (OR = 2.22, 95% CI = 1.58-3.10) compared to the Arg/Arg genotype. The gene-gene interaction of MDM2 and TP53 polymorphisms increased adult NPC risk in a more than multiplicative manner (OR for the presence of both MDM2 GG and TP53 Pro/Pro genotypes = 7.75, 95% CI = 3.53-17.58).

Conclusion: The findings suggest that polymorphisms of MDM2 and TP53 genes may be genetic modifier for developing NPC.

Citing Articles

Genetic polymorphisms in FABP2, CYP2E1, and TP53 genes are potentially associated with colorectal cancer susceptibility.

Ijaz M, Chen C, Iqbal R, Farooq H, Mehmood R, Asif M Sci Rep. 2024; 14(1):20464.

PMID: 39242607 PMC: 11379967. DOI: 10.1038/s41598-024-70381-y.

Identification of Novel Kinase-Transcription Factor-mRNA-miRNA Regulatory Network in Nasopharyngeal Carcinoma by Bioinformatics Analysis.

Gao L, Zhou L, Huang X Int J Gen Med. 2021; 14:7453-7469.

PMID: 34744455 PMC: 8566004. DOI: 10.2147/IJGM.S327657.

Deciphering the Pharmacological Mechanism of the Herb in the Treatment of Nasopharyngeal Carcinoma by Integrating iTRAQ-Coupled 2-D LC-MS/MS Analysis and Network Investigation.

Feng X, Shi H, Chao X, Zhao F, Song L, Wei M Front Pharmacol. 2019; 10:253.

PMID: 30936832 PMC: 6431671. DOI: 10.3389/fphar.2019.00253.

The frequency of R72P and 309T>G polymorphisms in Iranian infertile men with spermatogenetic failure: A case-control study.

Ebrahim Abadi Z, Khademi Bami M, Golzadeh M, Kalantar S, Sheikhha M Int J Reprod Biomed. 2018; 16(8):491-496.

PMID: 30288482 PMC: 6163049.

Detection of nasopharyngeal carcinoma susceptibility with single nucleotide polymorphism analysis using next-generation sequencing technology.

Wu M, Huang S, Yang F, Qin X, Liu D, Ding Y Oncotarget. 2017; 8(32):52708-52723.

PMID: 28881764 PMC: 5581063. DOI: 10.18632/oncotarget.17085.

References

Dumont P, Leu J, Della Pietra 3rd A, George D, Murphy M . The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003; 33(3):357-65. DOI: 10.1038/ng1093. View

Bond G, Hu W, Bond E, Robins H, Lutzker S, Arva N . A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5):591-602. DOI: 10.1016/j.cell.2004.11.022. View

Ara S, Lee P, Hansen M, Saya H . Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990; 18(16):4961. PMC: 332028. DOI: 10.1093/nar/18.16.4961. View

Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G . Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999; 19(2):1092-100. PMC: 116039. DOI: 10.1128/MCB.19.2.1092. View

Zhou G, Zhai Y, Cui Y, Zhang X, Dong X, Yang H . MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res. 2007; 13(9):2627-33. DOI: 10.1158/1078-0432.CCR-06-2281. View

Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T . Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis. 2007; 28(9):1996-2001. DOI: 10.1093/carcin/bgm168. View

Runnebaum I, Tong X, Moebus V, Heilmann V, Kieback D, Kreienberg R . Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines. Hum Genet. 1994; 93(6):620-4. DOI: 10.1007/BF00201559. View

Golubovskaya V, Conway-Dorsey K, Edmiston S, Tse C, Lark A, Livasy C . FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer. 2009; 125(7):1735-8. PMC: 2773794. DOI: 10.1002/ijc.24486. View

Zhuo X, Cai L, Xiang Z, Zhuo W, Wang Y, Zhang X . TP53 codon 72 polymorphism contributes to nasopharyngeal cancer susceptibility: a meta-analysis. Arch Med Res. 2009; 40(4):299-305. DOI: 10.1016/j.arcmed.2009.03.006. View

10.

Malkin D, Li F, Strong L, Fraumeni Jr J, Nelson C, Kim D . Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-8. DOI: 10.1126/science.1978757. View

11.

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

12.

Gryshchenko I, Hofbauer S, Stoecher M, Daniel P, Steurer M, Gaiger A . MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol. 2008; 26(14):2252-7. DOI: 10.1200/JCO.2007.11.5212. View

13.

Olivier M, Eeles R, Hollstein M, Khan M, Harris C, Hainaut P . The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002; 19(6):607-14. DOI: 10.1002/humu.10081. View

14.

Momand J, Jung D, Wilczynski S, Niland J . The MDM2 gene amplification database. Nucleic Acids Res. 1998; 26(15):3453-9. PMC: 147746. DOI: 10.1093/nar/26.15.3453. View

15.

Palmero E, Schuler-Faccini L, Caleffi M, Achatz M, Olivier M, Martel-Planche G . Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 2008; 261(1):21-5. DOI: 10.1016/j.canlet.2007.10.044. View

16.

Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G . p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995; 85(6):1580-9. View

17.

Brennan P . Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?. Carcinogenesis. 2002; 23(3):381-7. DOI: 10.1093/carcin/23.3.381. View

18.

FREEDMAN D, Levine A . Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1999; 59(1):1-7. View

19.

Bittenbring J, Parisot F, Wabo A, Mueller M, Kerschenmeyer L, Kreuz M . MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians. BMC Cancer. 2008; 8:116. PMC: 2375899. DOI: 10.1186/1471-2407-8-116. View

20.

Malkin D . p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet. 1993; 66(2):83-92. DOI: 10.1016/0165-4608(93)90233-c. View